BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24551095)

  • 1. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
    Janssen PM; Murray JD; Schill KE; Rastogi N; Schultz EJ; Tran T; Raman SV; Rafael-Fortney JA
    PLoS One; 2014; 9(2):e88360. PubMed ID: 24551095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
    Lowe J; Floyd KT; Rastogi N; Schultz EJ; Chadwick JA; Swager SA; Zins JG; Kadakia FK; Smart S; Gomez-Sanchez EP; Gomez-Sanchez CE; Raman SV; Janssen PM; Rafael-Fortney JA
    J Neuromuscul Dis; 2016; 3(3):395-404. PubMed ID: 27822449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.
    Rafael-Fortney JA; Chimanji NS; Schill KE; Martin CD; Murray JD; Ganguly R; Stangland JE; Tran T; Xu Y; Canan BD; Mays TA; Delfín DA; Janssen PM; Raman SV
    Circulation; 2011 Aug; 124(5):582-8. PubMed ID: 21768542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutraceutical and pharmaceutical cocktails did not preserve diaphragm muscle function or reduce muscle damage in D2-mdx mice.
    Spaulding HR; Quindry T; Quindry JC; Selsby JT
    Exp Physiol; 2020 Jun; 105(6):989-999. PubMed ID: 32267561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
    Gutpell KM; Hrinivich WT; Hoffman LM
    PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise.
    Lowe J; Kadakia FK; Zins JG; Haupt M; Peczkowski KK; Rastogi N; Floyd KT; Gomez-Sanchez EP; Gomez-Sanchez CE; Elnakish MT; Rafael-Fortney JA; Janssen PML
    J Neuromuscul Dis; 2018; 5(3):295-306. PubMed ID: 30010143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
    Spurney CF; Sali A; Guerron AD; Iantorno M; Yu Q; Gordish-Dressman H; Rayavarapu S; van der Meulen J; Hoffman EP; Nagaraju K
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):87-95. PubMed ID: 21304057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy.
    Delfín DA; Xu Y; Peterson JM; Guttridge DC; Rafael-Fortney JA; Janssen PM
    J Transl Med; 2011 May; 9():68. PubMed ID: 21586145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.
    van Putten M; Hulsker M; Young C; Nadarajah VD; Heemskerk H; van der Weerd L; 't Hoen PA; van Ommen GJ; Aartsma-Rus AM
    FASEB J; 2013 Jun; 27(6):2484-95. PubMed ID: 23460734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.
    van Putten M; Kumar D; Hulsker M; Hoogaars WM; Plomp JJ; van Opstal A; van Iterson M; Admiraal P; van Ommen GJ; 't Hoen PA; Aartsma-Rus A
    Neuromuscul Disord; 2012 May; 22(5):406-17. PubMed ID: 22284942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.
    Boulanger Piette A; Hamoudi D; Marcadet L; Kyomi Labelle F; Ovidiu David R; Bossé S; Argaw A; Frenette J
    PLoS One; 2018; 13(6):e0198408. PubMed ID: 29879154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifelong quercetin enrichment and cardioprotection in Mdx/Utrn+/- mice.
    Ballmann C; Denney TS; Beyers RJ; Quindry T; Romero M; Amin R; Selsby JT; Quindry JC
    Am J Physiol Heart Circ Physiol; 2017 Jan; 312(1):H128-H140. PubMed ID: 27836895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
    J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.